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Virtually	   any	   cell	   type	   in	   a	   mammalian	   organism	   uses	   Acetyl	   CoA	   to	   yield	   mevalonate,	  
through	   the	  activity	  of	   the	  3-­‐hydroxy-­‐3-­‐methyl-­‐glutaryl-­‐CoA (HMG-­‐CoA)	   reductase	  enzyme	  
and,	   ultimately,	   cholesterol.	   Statins	   have	   long	   and	   quite	   successfully	   been	   used	   as	  
cholesterol	  lowering	  drugs.	  They	  reversibly	  inhibit	  the	  HMG-­‐CoA	  reductase	  activity,	  which	  is	  
rate	   limiting	   in	   the	   early	   steps	   of	   the	   cholesterol	   synthesis	   pathway.	   In	   addition	   to	   these	  
effects,	   it	   has	   also	   been	   amply	   shown	   that	   statins	   may	   efficiently	   trigger	   cancer	   cell	  
apoptosis,	  making	  them	  a	  plausible	  therapeutic	  option	  for	  the	  treatment	  of	  cancer.	  Whether	  
statins	   may	   prevent	   from	   cancer	   occurrence	   is	   a	   matter	   of	   debate	   and	   an	   unanswered	  
question,	   but	   no	   doubt	   experimental	   models	   have	   clearly	   demonstrated	   the	   potential	   of	  
statins	   as	   direct	   cytotoxic	   agents,	   which	   can	   reduce	   tumor	   development	   or	   metastasis	  
spreading,	  even	  more	  so	  when	  combined	  to	  cytotoxic	  drugs.	  Until	  now,	  however,	  only	  few	  
data	   in	   humans	   support	   the	   idea	   that	   statins	   could	   rightfully	   enter	   the	   contingent	   of	  
anticancer	  drugs.	  Nevertheless,	  at	  times	  where	  cancer	  cells	  metabolism	  is	  getting	  very	  much	  
revisited,	  the	  mevalonate	  pathway	  has	  recently	  been	  reported	  as	  truly	  oncogenic,	  bringing	  
upfront	  the	  attractive	  possibility	  to	  see	  mevalonate	  pathway	  blunting	  agents,	  such	  as	  statins,	  
join	  the	  wealth	  of	  anticancer	  drugs.	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1-­‐Introduction	  
1.1-­‐The	  mevalonate	  pathway	  
The	   so-­‐called	   mevalonate	   pathway	   (Figure	   1)	   initiates	   with	   the	   enzymatic	   conversion	   of	  
acetoacetyl-­‐CoA	  into	  3-­‐hydroxy-­‐3-­‐methylglutaryl-­‐CoA	  (HMG-­‐CoA)	  catalyzed	  by	  the	  HMG-­‐CoA	  
synthase	   [1].	   HMG-­‐CoA	   is	   next	   converted	   into	   mevalonate	   in	   a	   rate-­‐limiting	   reaction	  
catalyzed	  by	  the	  HMG-­‐CoA	  reductase.	  Ensues	  a	  series	  of	  27	  biochemical	  reactions	  that	  lead	  
to	   cholesterol	   synthesis.	   Importantly,	   this	   pathway	   also	   generates	   prenyl	   carbon	   chains,	  
farnesyl	   pyrophosphate	   (FPP)	   and	   geranyl	   geranyl	   pyrophosphate	   (GGPP),	   which	   are	  
mandatorily	  added,	  in	  a	  post-­‐translational	  fashion,	  to	  the	  C-­‐terminus	  of	  several	  proteins	  that	  
contain	   a	   CAAX	   motif	   [1],	   [2].	   This	   prenylation	   reaction	   allows	   proteins,	   such	   as	   small	  
GTPases	   from	   the	   Ras	   and	   Rho	   families,	   to	   anchor	   to	   the	   inner	   plasma	   membrane	   and	  
acquire	  their	  enzymatic	  activities.	  Hence,	  a	  restriction	  in	  activity	  of	  the	  mevalonate	  pathway	  
imposed,	  for	  example,	  by	  a	  blockage	  in	  the	  very	  early	  steps,	  results	   in	  shortage	  of	  FPP	  and	  
GGPP,	   thereby	   preventing	   these	   GTPases	   from	   gaining	   functional	   activity.	   A	   schematic	  
summary	  of	  the	  signaling	  pathways	  is	  shown	  in	  Figure	  2.	  Other	  effects	  induced	  by	  blunting	  
the	   mevalonate	   pathway	   include,	   in	   addition	   to	   cholesterol	   restriction,	   a	   drop	   in	   the	  
production	   of	   active	   dolichol,	   Heme	   A	   or	   ubiquinone	   that	   fulfill	   important	   functions	   in	  
protein	  glycosylation	  or	  cell	  respiration.	  	  
1.2-­‐Statins,	  pharmacology	  and	  mechanism	  of	  action	  
Statins	   have	   been	   developed	   from	   natural	   compounds	   isolated	   from	   fungi.	   Mevastatin	  
(compactin,	   ML-­‐236B)	   was	   purified	   from	   Penicillium	   citrinum	   and	   lovastatin	   (Mevinolin,	  
Monacolin	  K)	  from	  Aspergillus	  terreus	  [3].	  Later,	  synthetic	  statins	  were	  developed,	  including	  
fluvastatin,	  simvastatin,	  or	  pravastatin.	  Remarkably,	  the	  Ki	  value	  for	  inhibition	  of	  the	  HMG-­‐
CoA	  reductase	  is	  1x10-­‐9	  M,	  whereas	  the	  Km	  Value	  for	  the	  enzyme	  and	  its	  natural	  substrate	  
HMG-­‐CoA	   is	   1x10-­‐5	  M.	  Mevastatin	  was	   then	   shown	   to	   be	   highly	   active	   at	   inhibiting	   sterol	  
synthesis	   in	   live	   human	   cells	   at	   nanomolar	   concentrations	   [4,	   5].	   In	   addition,	  micromolar	  
concentrations	  inhibited	  cell	  growth	  and	  altered	  cell	  morphology,	  which	  was	  reversed	  by	  the	  
addition	  of	  small	  amounts	  of	  mevalonate,	  the	  product	  of	  the	  HMG-­‐CoA	  reductase	  enzyme,	  
but	   not	   cholesterol,	   the	   end	   product	   of	   the	   pathway	   [6].	   The	   selection	   of	   mevastatin	  
resistant	  hamster	  cells	  showed	  that	  the	  HMG-­‐CoA	  reductase	  gene	  had	  been	  amplified,	  and	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the	  protein	  stabilized	  [7].	  This	  and	  further	  experiments	   led	  to	  the	   isolation	  of	  the	  gene.	  As	  
one	  major	  consequence	  of	  the	  activity	  of	  the	  mevalonate	  pathway,	  several	  cellular	  proteins	  
are	   modified	   through	   the	   post-­‐translational	   addition	   of	   prenyl	   (FPP	   or	   GGPP)	   groups,	  
including	  p21ras	  GTPase	  or	  lamin	  B	  [8-­‐11],	  suggesting	  that	  the	  activity	  of	  these	  proteins	  could	  
be	   strongly	   dependent	   on	   that	   of	   the	   pathway.	   Since	   that	   time,	   numerous	   studies	   have	  
addressed	  the	  myriad	  of	  consequences	  of	  statin	  treatment	  in	  various	  models,	  including	  cells	  
in	  culture	  and	  laboratory	  animals.	  	  
Important	   species	   to	   species	   differences	   in	   the	   activity	   of	   statins	   could,	   however,	   occur	  
between	  rodents	  and	  humans,	  who	  exhibit	  a	  unique	  profile	  of	  drug	  metabolizing	  enzymes,	  
making	   it	  hazardous	  to	  transpose	  data	  obtained	   in	  rodents	  directly	  to	  humans.	   In	  humans,	  
statins	  are	  subject	  to	  various	  metabolic	  transformations	  that	  maybe	  associated,	  collectively,	  
with	  transient	  liver	  dysfunction	  in	  a	  modest	  1%	  of	  the	  cases	  [12].	  Indeed,	  a	  few	  cases	  of	  liver	  
injury	   have	   been	   reported,	  with	   atorvastatin	   and	  mevastatin	   [13].	   Atorvastatin,	   lovastatin	  
and	   simvastatin	   are	  metabolized	   by	   CYP3A4,	   fluvastatin	   and	   rosuvastatin	   by	   CYP2C9,	   and	  
pravastatin	  -­‐	   the	  only	  water-­‐soluble	  statin	  -­‐	  undergoes	  sulfation.	   In	  addition,	  these	  hepatic	  
first	   pass	   metabolisms	   lead	   to	   production	   of	   either	   active	   (atorvastatin,	   lovastatin,	  
simvastatin)	  or	  inactive	  (fluvastatin,	  pravastatin)	  metabolites.	  All	  statins,	  but	  fluvastatin,	  are	  
substrate	   of	   drug	   transporter	   proteins.	   Taken	   together,	   these	  metabolic	   characteristics	   of	  
statins	  make	   these	   compounds	   prone	   to	   engage	   in	   drug-­‐drug	   interactions,	   especially	   CYP-­‐
dependent	   interactions.	   Nevertheless,	   drug-­‐drug	   interactions	   -­‐	   involving	   statins	   and	  
cyclosporine,	   fibrates	   or	   niacin	   among	   several	   others	   -­‐	   have	   been	   reportedly	   rare.	  
Nevertheless,	  a	  few	  fatal	  cases	  (0.15	  deaths	  per	  million)	  resulting	  from	  rhabdomyolysis	  have	  
been	  registered,	  which	  led	  to	  the	  removal	  of	  cerivastatin	  from	  the	  market.	  These	  data	  show	  
that	   statins	   may	   be	   harmful,	   but	   at	   rather	   low	   frequency,	   in	   the	   general	   population	  
undergoing	   statin	   therapy	   to	   treat	   high	   cholesterol	   levels.	   In	   addition,	   dose-­‐escalating	  
regimen	   in	   short	   time	   treatments,	   once	   administered	   to	   cancer	   patients,	   showed	   good	  
tolerance,	  up	  to	  415	  mg/m2	  lovastatin,	  and	  peak	  plasma	  concentrations	  as	  high	  as	  12.3	  µM	  
lovastatin	  [14].	  
A	  major	   discovery	  was	   that	   from	   the	  Brown	  and	  Goldstein	   Laboratory	  who	  unraveled	   the	  
feedback	  mechanism	  evoked	  by	  statins	  on	  the	  mevalonate	  pathway.	  Indeed,	  they	  elegantly	  
demonstrated	   that	   the	   endoplasmic	   reticulum	  was	   able	   to	   perceive	   a	   drop	   in	   cholesterol	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concentration,	  thereby	  stimulating	  back	  a	  rise	  in	  the	  activity	  of	  the	  pathway.	  This	  is	  operated	  
through	  the	  release	  of	  the	  Sterol	  Response	  Element	  Binding	  proteins	   (SREBP),	   from	  the	  ER	  
membrane,	  their	  proteolysis	  in	  the	  Golgi	  apparatus,	  giving	  rise	  to	  N-­‐terminal	  fragments	  that	  
then	  enter	   the	  nucleus	   to	  serve	  as	   transcriptional	  activators	  of	  virtually	  all	  genes	   from	  the	  
mevalonate	  pathway	  [1].	  This	  mechanism	  regulates	  the	  balance	  between	  cholesterol	  intake	  
via	  Low	  Density	  Lipoproteins	  and	  endogenous	  synthesis.	  
An	  important	  consequence	  of	  blunting	  the	  mevalonate	  pathway	  with	  statins	  is	  the	  blockage	  
of	  the	  prenylation	  of	  small	  GTPases,	  including	  Ras,	  Rho,	  Rac	  or	  cdc42.	  Because	  these	  proteins	  
are	  involved	  in	  the	  control	  of	  cell	  division,	  shape	  or	  motility,	  they	  play	  major	  roles	  in	  cancer.	  
In	   addition,	   they	   may	   even	   gain	   proliferative	   potential	   through	   acquired	   activating	  
mutations.	   Hence,	   when	   p21ras	   farnesylation	   was	   shown	   to	   be	   strongly	   decreased	   in	  
response	  to	  statins,	  it	  came	  as	  a	  real	  hope	  that	  statins,	  or	  else	  farnesyl	  transferase	  inhibitors,	  
could	  be	  used	  to	  treat	  cancer.	  	  	  
2-­‐Cancer,	  epidemiological	  data	  	  
2.1-­‐Incidence	  of	  cancer	  
Statins	   are	   widely	   used	   to	   lower	   cholesterol	   levels,	   and	   millions	   of	   people	   are	   treated	  
worldwide	  annually.	  Hence,	  several	  very	  large	  cohorts	  of	  patients	  have	  been	  followed	  over	  
the	  years,	  demonstrating	  the	  highly	  beneficial	   impact	  of	  statins	  on	  cardiovascular	  diseases.	  
These	   cohorts	   were	   also	   used	   to	   question	   the	   possible	   impact	   of	   statins	   on	   cancer	  
occurrence.	  However,	  because	  these	  studies	  were	  conducted	  in	  a	  retrospective	  manner,	  the	  
conclusions	  might	  not	  be	  rightfully	  interpreted	  or	  even	  be	  erroneous.	  Nevertheless,	  a	  large	  
amount	  of	  data	  was	  collected.	   In	  essence,	  either	  one	  of	   two	  conclusions	  were	  attained.	   In	  
several	   studies,	   statins	   could	   prevent	   cancer	   occurrence,	   by	   up	   to	   50%,	   or,	   in	   others,	   no	  
protective	   effects	   were	   registered.	   Nevertheless,	   it	   now	   seems	   that	   statins	  may	   be	  more	  
beneficial	  than	  detrimental	  in	  acting	  on	  cancer.	  
Originally,	   the	   Prosper	   [15]	   study	   had	   suggested	   that	   pravastatin	   could	   increase	   cancer	  
incidence	   in	   subjects	   over	   75.	   However,	   this	   was	   not	   confirmed	   in	   further	   studies,	   which	  
showed	  no	  increase	  [16].	  Among	  10	  000	  subjects	  from	  the	  Heart	  Protection	  Study,	  there	  was	  
no	   difference	   in	   death	   numbers	   among	   subjects	   taking	   simvastatin	   compared	   to	   placebo	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[17].	  In	  patients	  under	  statin	  therapy,	  there	  was	  no	  relationship	  between	  the	  level	  of	  LDL-­‐C	  
reduction	  and	  the	  risk	  of	  cancer,	  but	  a	  surprising	  inverse	  relationship	  between	  achieved	  LDL-­‐
C	   levels	   and	   rates	   of	   newly	   diagnosed	   cancer	   [18].	  In	   addition,	   large	   studies	   revealed	   no	  
differences	   between	   the	   statin	   and	   the	   placebo	   groups	   from	   the	   Cholesterol	   Treatment	  
Trialist	  studies	  [19,	  20].	  Furthermore,	  statins	  -­‐	  taken	  for	  over	  one	  year	  -­‐	  were	  not	  associated	  
with	  increased	  risk	  for	  13	  distinct	  cancer	  types	  [21].	  This	  study	  also	  showed	  that	  untreated	  
hyperlipidemia	  was	  associated	  with	  slightly	  higher	  incidence	  of	  colon,	  bladder	  and	  prostate	  
cancer.	  Other	  epidemiological	  studies	  did	  not	  detect	  modified	  cancer	  risk	  levels	  in	  response	  
to	  statins	  [22,	  23].	  As	  reviewed	  recently,	  no	  beneficial	  or	  detrimental	  effects	  of	  statin	  usage	  
in	  cancer	  incidence	  were	  recorded	  for	  prostate,	  breast,	  colorectal,	   lung,	  bladder,	  renal	  cell,	  
or	   pancreatic	   cancer,	   but	   potential	   protective	   effects	   were	   observed	   for	   melanoma,	  
endometrial	  cancer	  and	  non-­‐Hodgkin	  lymphoma	  [13].	  	  
Overall,	   the	  apparent	  discrepancies	  between	  studies	  may	  originate	   from	  differences	   in	   the	  
analytical	  methods	  and	  populations,	  lack	  of	  clear	  dose	  or	  duration	  of	  statin	  exposure,	  which	  
was	  often	  relatively	  short	  with	  respect	  to	  the	  time	  required	  to	  develop	  cancers.	  In	  addition,	  
and	  most	  importantly,	  the	  vast	  majority	  of	  studies	  was	  retrospective,	  and	  was	  not	  designed	  
to	  address	  the	  question	  of	  cancer	  incidence,	  but	  the	  effect	  on	  cardiovascular	  diseases	  [24].	  
Several	   additional	   factors	   of	   variation	   in	   the	   sensitivity	   to	   statins	   have	   been	   recorded.	  
HMGCR	   gene	   SNP	   alleles	   dictate	   the	   structure,	   and	   hence	   the	   activity,	   of	   the	   enzyme.	  
Indeed,	  depending	  on	  several	  SNPs	  in	  the	  gene,	  the	  enzyme,	  which	  is	  normally	  assembled	  as	  
a	  homotetramer,	  may	  be	  composed	  of	  full-­‐length	  monomers	  and	  truncated	  monomers	  due	  
to	   the	   SNP-­‐dependent	   alternative	   splice	   product	   devoid	   of	   exon	   13	   that	   encodes	   a	  
subdomain	  important	  for	  statin	  interaction	  [25].	  	  In	  addition,	  several	  very	  elegant	  and	  recent	  
studies	  have	  demonstrated,	   in	  experimental	  models	  of	  breast	  cancer,	   that	   the	  mevalonate	  
pathway	   is	   a	   true	   oncogenic	   pathway,	   often	   overactive	   in	   cancer	   cells	   [26].	   Furthermore,	  
mutant	  forms	  of	  p53	  gain	  a	  novel	  function	  in	  recruiting	  SREBP	  transcription	  factors	  onto	  the	  
genes	   from	   the	  mevalonate	  pathway,	   thereby	  amplifying	   its	   activity	   [27].	   These	   important	  
experimental	   data	   strongly	   reinforce	   the	   concept	   that	   blunting	   the	   pathway	   is	   a	   relevant	  
strategy	  to	  combat	  cancer.	  Furthermore,	  breast	  cancer	  stem	  cells	  can	  also	  be	  sensitized	  by	  
the	  use	  of	  statins,	  as	  a	  result	  of	  the	  high	  activity	  of	  the	  mevalonate	  pathway	  [28].	  
	  
An	  early	  study	  showed	  that	  lovastatin	  reduced	  slightly	  cancer	  incident	  cases	  (14	  cases	  in	  the	  
	   6	  
lovastatin	   group	   vs	   21	   cases	   in	   the	   reference	   group)	   [29].	   Other	   studies	   showed	   20-­‐28%	  
reduction	  of	  cancer	  incidence	  by	  statins	  [22,	  30].	  Reduced	  incidence	  of	  melanoma	  and	  colon	  
cancer	   was	   also	   reported	   [22,	   31,	   32].	   In	   a	   land	   marking	   paper	   by	   Poynter	   [33],	   it	   was	  
observed	   that	   an	   Israeli	   cohort	   of	   subjects	   under	   statin	   therapy	   for	   5	   years	   showed	   an	  
impressive	  50%	   reduction	   in	   colon	   cancer	   cases.	  However,	   a	   very	   large	   survey	  of	   132	  136	  
men	  and	  women	  did	  not	  show	  any	  such	  reduction	  in	  colon	  cancer	  incidence	  [34]	  [35]	  [10,	  36,	  
37].	  A	   series	  of	   studies	   in	   independent	  population	   sets	   showed	   that	   cancer	   incidence	  was	  
reduced	  by	   statins,	   including	   colon	   [35],	   liver	   [38],	   [35],	   breast,	   skin,	   prostate,	  melanoma,	  
head	   and	   neck	   [39-­‐44],	   lung	   [45]	   or	   pancreatic	   cancers	   [45,	   46].	   Interestingly,	   statin	  
treatment	  was	  associated	  with	  a	   reduced	  number	  of	  colon	  adenomatous	  polyps,	   including	  
advanced	   forms,	   and	   a	   smaller	   size,	   suggesting	   that	   the	   beneficial	   effects	   of	   statins	   could	  
originate	   early	   in	   the	   course	   of	   tumor	   progression	   [47].	   A	   preclinical	   model	   of	   liver	  
carcinogenesis	  showed	  that	  lovastatin	  reduced	  the	  number	  of	  tumor	  nodules,	  an	  effect	  that	  
was	  partially	  antagonized	  by	  supplementation	  with	  ubiquinone.	  This	  occurred	  in	  absence	  of	  
modification	  in	  cholesterol	  levels,	  suggesting	  that	  cholesterol	  shortage	  is	  not	  responsible	  for	  
the	  sensitivity	  to	  statins,	  as	  also	  observed	  in	  many	  experimental	  in	  vitro	  systems	  (see	  above)	  
[48].	   Interestingly,	   it	   has	   been	   proposed	   to	   take	   advantage	   of	   the	   anti-­‐inflammatory	  
properties	   of	   statins	   to	   oppose	   the	   deleterious	   effects	   of	   ionizing	   radiation	   (IR),	   including	  
normal	   tissue	   fibrosis	   [49].	   Statins	   can	   indeed	   restrict	   IR-­‐induced	   NFkB	   activation,	   which	  
promotes	  expression	  of	  inflammatory	  cytokines	  [50,	  51].	  In	  addition,	  statins	  were	  shown	  to	  
improve	   radiation-­‐induced	   intestine	   injury	   [52,	  53],	   among	  other	  effects	   like	  promotion	  of	  
double	  DNA	  strand	  breaks	  repair.	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2.2-­‐Experimental	  cancer	  models:	  the	  promise	  of	  statins	  	  
Many	  studies	  have	  reported	  the	  cytotoxic	  effects	  exerted	  by	  statins	  in	  various	  experimental	  
setups.	   Strikingly,	   although	   direct	   toxicity	   to	   normal	   cells	   from	   the	   muscle	   [54]	   or	   the	  
endothelia	  was	   reported,	  most	  normal	   cell	   types	  are	   largely	  unaffected	  by	   statins	   [44,	  55-­‐
58].	   By	   contrast,	   strong	   toxicity	   is	   induced	   in	   many	   diverse	   cancer	   cells,	   and	   quite	   often	  
results	   in	   apoptosis.	   This	   preferential	   activity	   towards	   cancer	   cells	   has	  made	   statins	   good	  
candidates	  to	  target	  these	  cells	  and	  drive	  them	  to	  undergo	  programmed	  cell	  death.	  Virtually	  
any	   cancer	   type,	   from	   hematological	   to	   solid	   tumors,	   has	   been	   shown	   to	   be	   sensitive	   to	  
statins.	  Within	  the	  scope	  of	  this	  review,	  we	  will	  mostly	   focus	  on	  digestive	  cancers,	  and	  we	  
certainly	  apologize	  for	  not	  referring	  to	  some	  of	  the	  very	  numerous	  articles	  in	  the	  field.	  	  
2.2.1-­‐Pancreatic	  cancer	  
Pancreatic	  cancer,	  which	  is	  much	  deadly,	  has	  been	  the	  subject	  of	  several	  studies.	  Pancreas	  
tumor	  cell	   invasion	   in	   vitro,	   and	   liver	  metastasis	   from	  xenografts	   in	  mice	  were	   reduced	  or	  
prevented	   by	   fluvastatin,	   and	   rescued	   in	   vitro	   with	   all-­‐trans-­‐geranyl-­‐geraniol.	   The	   in	   vitro	  
suppression	  effect	  was	  associated	  with	  a	  blockade	  of	  RhoA	  translocation	  from	  the	  cytosol	  to	  
the	  membrane	   fraction,	   thereby	   reducing	   its	   GTPase	   activity	   [59].	   In	   addition,	   fluvastatin	  
treatment	  of	  MIAPaCa-­‐2	  cells	  with	  a	  codon	  12	  mutant	  p21ras	  induced	  apoptosis,	  which	  was	  
prevented	  by	  the	  addition	  of	  mevalonic	  acid.	  Fluvastatin	   induced	  deoxycytidine	  kinase,	  the	  
enzyme	   responsible	   for	   gemcitabine	   activation.	   Consequently,	   the	   addition	   of	   both	  
fluvastatin	  and	  gemcitabine	  was	  even	  more	  potent	  at	  triggering	  cell	  apoptosis,	  and	  reducing	  
tumor	   growth	   in	   animals	   [60].	   Importantly,	   this	   latter	   study	   suggests	   that	   tumors	   carrying	  
activating	   ras	   mutations	   could	   also	   be	   treated	   by	   statins.	   The	   various	   statins	   were	   also	  
described	  to	  induce,	  to	  different	  extents,	  the	  death	  of	  CAPAN-­‐2,	  BxPc-­‐3	  and	  MiaPaCa-­‐2	  cells,	  
simvastatin	  being	  the	  most	  potent	  in	  vitro,	  and	  rosuvastatin	  in	  vivo.	  This	  strong	  toxicity	  was	  
always	  associated	  with	   impairment	  of	  ras	  translocation	  to	  the	  plasma	  membrane	  [61].	  The	  
Akt/PKB	  and/or	  the	  NFKB	  and	  Raf/MEK	  survival	  pathways	  were	  inhibited	  by	  atorvastatin	  in	  
Panc-­‐1	   and	   MiaPaCa-­‐2	   cells,	   which	   sensitized	   the	   cells	   further	   to	   combinations	   with	  
gemcitabine	   and	   5-­‐Fluorouracile.	   These	   responses	   were	   dependent	   on	   expression	   of	   the	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P2X7	   purinergic	   receptor	   [62].	   Finally,	   simvastatin	   was	   a	   much	   stronger	   inducer	   of	   cell	  
toxicity	  than	  pravastatin,	  as	  shown	  by	  cell	  rounding	  and	  MTT	  assays	  [63].	  
2.2.2-­‐Gastric	  cancer	  
As	  other	  highly	  deadly	   cancers,	   gastric	   and	  esophageal	   cancers	  have	  also	  been	   challenged	  
with	  statins.	  The	  gastric	  carcinoma	  TE-­‐8	  and	  SKGT-­‐4	  cell	  lines	  were	  shown	  to	  be	  sensitive	  to	  
lovastatin,	   which	   suppressed	   viability	   and	   invasion,	   effects	   paralleled	   with	   reduced	  
expression	  of	  ErK1/2,	  c-­‐Jun	  and	  COX-­‐2.	  However,	  lovastatin	  did	  not	  prevent	  tumor	  growth	  in	  
mouse	   xenografts.	   We	   have	   shown	   recently	   that	   several	   statins,	   but	   not	   pravastatin,	  
triggered	  strong	   levels	  of	  apoptosis	   in	   the	  gastric	  cancer	  HGT-­‐1	  cell	   line,	  effects	  prevented	  
very	  efficiently	  by	  addition	  of	   geranyl	   geranyl	  pyrophosphate,	  mevalonate	  and,	   to	  a	   lower	  
extent,	   by	   farnesyl	   pyrophosphate	   or	   cholesterol	   [64].	   In	   addition,	   lovastatin	   induced	  
procaspase-­‐7	  in	  a	  transcriptional	  manner,	  as	  it	  did	  for	  caspase-­‐2	  in	  other	  digestive	  cell	  lines	  
[64],	   indicating	   that	   these	   caspases	   could	   be	   important	   drivers	   of	   the	   cytotoxic	   response	  
elicited	   in	   cancer	   cells.	   Furthermore,	   statin-­‐adapted	  HGT-­‐1	   cells	   grew	  more	   slowly	   in	   vitro	  
and	  in	  vivo	  when	  transplanted	  into	  immuno-­‐compromised	  mice,	  suggesting	  that	  adaptation	  
to	  statins	  could	  lower	  tumor	  growth	  in	  this	  model	  [65].	  
2.2.3-­‐Liver	  cancer	  
Apoptosis	   was	   triggered	   in	   Huh-­‐7	   and	   HepG2	   HCC	   cell	   lines	   by	   fluvastatin,	   together	   with	  
G0/G1	   cell	   cycle	   arrest,	   and	  a	  down-­‐regulation	  of	   the	  ERK1/2	  and	  an	  up-­‐regulation	  of	   the	  
MAP	   Kinase	   pathways	   [66].	   These	   effects	   were	   further	   amplified	   when	   statins	   were	  
combined	  with	  activators	  of	  the	  benzodiazepine	  receptors,	  which	  are	  often	  up-­‐regulated	  in	  
tumors,	  and	  could	  overcome	  chemoresistance	   imposed	  by	  overexpression	  of	  Bcl-­‐2	  [67-­‐69].	  
Pravastatin	  was	  much	  less	  active,	  and	  required,	  as	  in	  many	  if	  not	  all	  other	  cell	  models,	  very	  
high	   concentrations	   (above	   250	   µM)	   to	   manifest	   some	   pro-­‐apoptotic	   effects	   that	   were	  
somewhat	  magnified	   by	   benzodiazepine	   receptor	   activators.	   In	   addition,	   co-­‐treatments	   of	  
HepG2	  cells	  with	  EPA	  and	  lovastatin,	  two	  separate	  classes	  of	  HMG-­‐CoA	  reductase	  inhibitors,	  
amplified	  cell	   growth	  arrest,	  as	   compared	   to	   lovastatin	  alone	   [70].	  Another	   study	  showed,	  
using	   the	   same	   cell	   lines,	   that	   simvastatin	   induced	   apoptosis,	   G0/G1	   cell	   cycle	   arrest,	  
suppressed	   CDKs	   and	   up-­‐regulated	   p19	   and	   p27	   [71].	   The	   authors	   further	   showed	   that	  
simvastatin	   suppressed	   cell	   adhesion,	   paralleled	   by	   a	   decrease	   of	   B1,	   B2	   and	  A3	   integrins	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and	  a	  strong	  suppression	  of	  ROCK-­‐I	  in	  these	  cell	  lines	  [71].	  Treatment	  of	  Huh-­‐7	  HCC	  cells	  by	  
lovastatin	   induced	  apoptosis,	   an	  effect	   that	  was	   further	   amplified	  by	  enzastaurin,	   a	  PKC-­‐β	  
inhibitor,	   in	   a	   strategy	   developed	   to	   counteract	   the	   inductive	   effect	   of	   lovastatin	   on	   this	  
enzyme	  [72].	  In	  addition,	  tumors	  from	  MH134	  cells	  barely	  developed	  in	  immune-­‐competent	  
mice	   administered	   this	   drug	   combination.	   In	   another	   study,	   atorvastatin	   suppressed	  Myc-­‐
driven	   proliferation	   of	   human	   Huh-­‐7	   and	   HepG2	   cells	   in	   vitro	   and	   Myc-­‐induced	   HCC	   in	  
transgenic	  mice,	  effects	  that	  were	  correlated	  with	  the	  blockade	  of	  Myc	  phosphorylation,	  a	  
step	  catalyzed	  by	  Rac	  and	  necessary	  for	  its	  tumor-­‐promoting	  activity,	  and	  being	  suppressed	  
by	  the	  statin	  [73].	  Simvastatin	  triggered	  apoptosis	  of	  Hep3B	  and	  HepG2	  liver	  cancer	  cells,	  but	  
no	  direct	  correlation	  between	  the	  rates	  of	  cell	  death	  and	  the	   level	  of	  HMG-­‐CoA	  reductase	  
activity	  was	  observed	  [63].	  It	  was	  also	  demonstrated	  that	  the	  lack	  of	  cytotoxic	  effect	  of	  the	  
hydrophilic	  pravastatin	  was	  likely	  due	  to	  a	  poor	  uptake	  of	  the	  drug	  by	  cancer	  cells,	  which	  do	  
not	   express	   the	   OATP1B1	   specific	   transporter,	   whereas	   lipophilic	   statins	   enter	   the	   cells	  
readily.	  Geraniol	  and	  simvastatin,	  added	  at	  sub-­‐active	  concentrations,	  triggered	  HepG2	  cells	  
apoptosis	  [74].	  The	  induction	  of	  apoptosis	  by	  simvastatin	  in	  HepG2	  cells	  was	  associated	  with	  
some	   induction	  of	   the	  pro-­‐apoptotic	  BAX	  gene,	  and	  a	  mild	   reduction	   in	   the	  anti-­‐apoptotic	  
BCL-­‐2	  gene,	   suggesting	   that	  pre-­‐translational	  events	  could	  also	  participate	   in	   the	  cytotoxic	  
response	  of	   liver	  cells	   to	  statins	   [75].	   Importantly,	  pravastatin	  was	  shown	  to	  suppress	   lung	  
metastasis	  from	  HCC	  in	  a	  rat	  model,	  further	  suggesting	  a	  preventing	  effect	  of	  statins	  against	  
cancer	  spreading	  [76].	  
2.2.4-­‐Colon	  cancer	  
Several	  colon	  cancer	  cell	   lines	  (SW480,	  HCT116,	  LoVo	  and	  HT-­‐29)	  were	  shown	  to	  be	  highly	  
sensitive	   -­‐	   albeit	   to	   various	   degrees	   -­‐	   to	   apoptosis	   induction	   by	   lovastatin,	   an	   effect	  
accompanied	   by	   reduction	   of	   the	   anti-­‐apoptotic	   Bcl-­‐2	   and	   a	   rise	   of	   the	   pro-­‐apoptotic	   Bax	  
proteins	  [77].	  The	  same	  investigators	  demonstrated	  that	  the	  addition	  of	  GGPP,	  but	  not	  FPP,	  
fully	   prevented	   lovastatin-­‐induced	   apoptosis.	   Furthermore,	   lovastatin	   strongly	   potentiated	  
the	  death	   induction	  by	  5-­‐FU	  or	   cisplatin.	   This	  was	  quite	   remarkable	   for	  HT-­‐29	  cells,	  which	  
were	   otherwise	   barely	   affected	   by	   lovastatin	   alone.	   In	   both	   Ras	   wt	   and	   Ras	   mutant	   rat	  
intestinal	   cells,	   lovastatin	   triggered	   apoptosis	   [77].	   This	  was	   associated	  with	   a	   decrease	   in	  
the	   membrane	   bound	   RhoA	   and	   RhoB	   proteins,	   indicating	   that	   blunting	   the	   activity	   of	  
membrane-­‐bound	   Rho	   proteins	  was	   responsible	   for	   the	   apoptotic	   effects	   of	   the	   statin.	   In	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addition,	   simvastatin	   and	   lovastatin	   sensitized	   SW480	   cells	   to	   Trail-­‐induced	   apoptosis,	  
presumably	  upon	  increasing	  the	  fraction	  of	  cells	  arrested	  in	  G0/G1	  [78].	  CRC	  cell	  lines,	  either	  
sensitive	  or	  resistant	  to	  5-­‐FU,	  were	  readily	  pushed	  into	  apoptosis	  by	  cerivastatin,	  with	  up	  to	  
310-­‐fold	  increase	  in	  sensitivity,	  as	  compared	  to	  5-­‐FU	  alone	  [79].	  Cerivastatin	  suppressed	  NF-­‐
kB	  transcriptional	  activity,	  which	  is	  otherwise	  responsible	  for	  the	  induction	  of	  anti-­‐apoptotic	  
genes.	   Mevastatin	   blocked	   the	   progression	   of	   HCT116	   cells	   into	   the	   cell	   cycle	   through	  
activity	  of	  the	  cell	  cycle	  inhibitor	  p21.	  Cells	  with	  inactive	  p21	  were	  insensitive	  to	  mevastatin	  
[80].	   In	   addition,	   lovastatin	   suppressed	   the	   adhesion	  of	  HT29	   cells	   to	   endothelial	   cells,	   an	  
effect	  driven	  by	  E-­‐selectin,	  which	  expression	  was	  suppressed	  by	  lovastatin,	  lending	  support	  
to	  the	  notion	  that	  statins	  may	  reduce	  metastases	   [81].	   In	  a	  tumor	  prevention	  scheme,	  the	  
addition	   of	   atorvastatin	   reduced	   the	   occurrence	   of	   adenomatous	   polyps	   by	   70%	   in	   the	  
APCmin/+	   mouse	   model	   of	   colon	   carcinogenesis.	   This	   effect	   was	   further	   increased	   in	  
combining	   atorvastatin	   and	   celecoxib.	   As	   a	   response	   to	   treatment,	   apoptosis	   was	   readily	  
manifested	   in	   the	   adenocarcinomas	   in	   response	   to	   either	   drug	   or	   the	   combination	   [82].	  
However,	   conflicting	   results	   were	   also	   reported	   with	   the	   same	   mouse	   model,	   where	  
atorvastatin	   was	   efficient	   at	   reduced	   tumor	   growth	   but	   not	   polyp	   formation	   [83].	   These	  
discrepancies	  could	  likely	  be	  attributed	  to	  other	  effects	  linked,	  for	  example,	  to	  the	  types	  of	  
diet	  that	  differed	  between	  the	  two	  studies.	  Nevertheless,	  a	  recent	  study	  with	  pitavastatin	  in	  
the	  Min	  model	   also	   reported	  a	   reduced	  number	  of	   colon	  polyps	   [84].	   This	  was	  associated	  
with	  a	  drop	  in	  the	  expression	  of	  cyclooxygenase-­‐2,	  IL6,	  iNOS,	  MCP-­‐1	  and	  Pai-­‐1	  in	  the	  healthy	  
part	  of	   the	  colon.	  Among	   these	  effects,	  only	   iNOS	  expression	  was	  also	  detected	   in	  polyps,	  
providing	   evidence	   for	   an	   anti-­‐inflammatory	   effect	   of	   statins	   in	   pre-­‐cancerous	   lesions.	   In	  
another	   study,	   the	   atorvastatin+celecoxib	   combination	   induced	   p21Cip1/Waf1,	   p27Kip1,	   and	  
phospho-­‐JNK,	   decreased	   the	   levels	   of	   phospho-­‐AKT	   and	   hyper-­‐phosphorylated	   Rb.	   It	   also	  
selectively	  modified	  membrane	  localization	  of	  small	  G	  proteins	  (RhoA-­‐C)	  [85].	  CRC	  cell	  lines	  
were	  analyzed	  for	  their	  content	   in	  the	  bone	  morphogenetic	   factor	  2	  (BMP2),	   in	  relation	  to	  
their	   sensitivity	   to	   statins.	   It	   was	   found	   that	   cells	   expressing	   high	   levels	   of	   the	   protein	   in	  
response	  to	  statins	  (SAOS2,	  HCT116,	  DLD1)	  were	  much	  more	  sensitive	  to	  apoptosis	  induction	  
than	   cells	   (HT-­‐29,	   SW480)	   in	   which	   the	   BMP	   pathway	   was	   not	   activated	   by	   statins	   [86].	  
Activation	   of	   the	   BMP	   pathway	   was	   associated	   with	   high	   expression	   of	   SMAD4,	   which	  
suppression	  blocked	  activation	  of	   the	  pathway.	  Only	   tumors	   from	  statin-­‐sensitive	  cell	   lines	  
grown	   in	   mice	   were	   growth-­‐inhibited	   by	   simvastatin.	   These	   data	   suggested	   that	   statin-­‐
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induced	  cell	  death	  in	  CRC	  cell	  lines	  was	  strongly	  dependent	  on	  activity	  of	  the	  BMP	  pathway.	  
Recently,	  it	  was	  shown	  that	  the	  BMP2	  gene	  promoter	  was	  methylated	  in	  cell	  lines	  with	  the	  
hypermethylator	   phenotype	   and	   in	   tumors	   [87].	   Interestingly,	   statins	   could	   up-­‐regulate	  
expression	  of	  the	  DNA	  methyl	  transferase,	  leading	  to	  demethylation	  of	  the	  BMP2	  and	  other	  
genes,	   thereby	   inducing	   the	   transition	   from	   a	   stem-­‐like	   cell	   to	   a	   more	   differentiated	  
phenotype.	   This	   effect	  was	   accompanied	  by	   a	   rise	   in	   sensitivity	   to	   5-­‐FU.	   Tumor	   growth	   in	  
mice	  was	   also	   reduced	   by	   statins	   as	   a	   result	   of	   recovery	   of	   BMP2	   expression.	   In	   another	  
study,	  simvastatin	  triggered	  apoptosis	  of	  COLO-­‐205	  and	  HCT116	  CRC	  cell	  lines,	  together	  with	  
a	  decrease	  of	  Bcl-­‐2,	  Bcl-­‐xL,	   cIAP1	  and	  c-­‐FLIP.	   Tumors	   in	  mice	   showed	   increased	  apoptosis,	  
larger	   necrotic	   areas,	   and	   reduced	   angiogenesis,	   all	   effects	   being	   associated	  with	   reduced	  
tumor	   growth,	   in	   response	   to	   simvastatin	   [88].	   In	   addition,	   it	   was	   shown	   that	   lovastatin	  
suppressed	   survivin	   expression	   through	   antagonism	   of	   the	   Pi3K	   pathway,	   presumably	  
ensuing	  from	  blockade	  of	  ras	  farnesylation,	  in	  SW480	  cells	  [89].	  A	  recent	  study	  surveyed	  the	  
sensitivity	  to	  apoptosis	  as	  a	  function	  of	  KRAS	  mutations	  in	  CRC	  cell	  lines.	  Hence,	  low	  doses	  of	  
simvastatin	  (0.2	  µM)	  sensitized	  KRAS	  mutant	  cell	  lines	  (including	  LOVO	  and	  SW480),	  but	  not	  
BRAFV600E	  mutants	  (like	  HT29),	  which	  may	  be	  associated	  with	  cetuximab	  resistance	  [90].	  The	  
association	   of	   simavastatin	   and	   cetuximab,	   although	   a	   more	   powerful	   cell	   death	   inducer	  
than	  any	  drug	  alone	  on	  KRAS	  mutants,	  did	  not	  sensitize	  BRAF	  mutant	  cells	  in	  vitro	  or	  in	  vivo	  
in	  mice.	  Hence,	  simvastatin	  may	  overcome	  cetuximab	  resistance,	  depending	  on	  the	  presence	  
of	  BRAF	  mutations,	  in	  KRAS	  mutant	  CRC	  cells.	  Finally,	  a	  bioinformatics	  analysis	  of	  statin	  data	  
throughout	  the	  NCI	  60	  cell	  line	  panel	  identified	  genes	  involved	  in	  the	  resistance	  to	  lovastatin	  
and	   simvastatin	   using	   SNP	   mapping	   [91].	   The	   data,	   confirmed	   in	   RNAi	   experiments,	  
identified	  genes	  distinctively	   involved	  in	  resistance	  to	  either	  simvastatin	  or	   lovastatin.	  Only	  
the	   EAF2	   gene	   was	   common	   between	   the	   two	   statins,	   the	   silencing	   of	   which	   restored	  
sensitivity	   of	   HCT116	   cells	   to	   both	   statins,	   thereby	   validating	   the	   pharmacogenomics	  
approach.	  Nevertheless,	   EAF2	   silencing	  did	  not	   sensitize	   the	   chemotherapy	   resistant	  HT29	  
CRC	  cell	  line.	  In	  addition,	  lovastatin	  was	  shown	  to	  inhibit	  histone	  deacetylase	  activity,	  leading	  
to	   the	   stimulation	  of	  p21WAF/CIP-­‐dependent	   transcription.	   The	  effect	  was	  as	  pronounced	  as	  
that	   observed	   in	   response	   to	   trichostatin	   A	   or	   valproic	   acid,	   two	   bona	   fide	   histone	  
deacetylase	  inhibitors	  [38].	  
	  
3-­‐Cancer	  treatment:	  human	  trials	  
	   12	  
In	   view	   of	   the	   compelling	   pre-­‐clinical	   evidence	   that	   mevalonate	   restricting	   agents,	   like	  
statins,	  may	  help	  prevent	  but,	  more	  probably,	  treat	  cancer,	  a	  number	  of	  prospective	  studies	  
are	  underway,	  or	  will	  soon	  be,	  as	  recorded	  by	  the	  clinicaltrials.gov	  web	  site.	  As	  of	  November	  
2,	   2012,	   interrogating	   “statins”	   AND	   “cancer”	   yields	   66	   entries	   related	   to	   cancer;	   among	  
these,	  13	  for	  breast,	  12	  for	  hematological	  diseases,	  9	  for	  prostate,	  9	  for	  CRC,	  8	  for	  lung,	  3	  for	  
liver,	  2	  for	  gynecological	  cancers,	  2	  for	  gastric	  cancer,	  2	  for	  melanoma,	  1	  for	  pancreas,	  1	  for	  
bone	  and	  1	   for	  kidney.	  Hence	  digestive	  diseases	  account	   for	  15	   trials,	  CRC	  being	   the	  most	  
represented.	   Up	   to	   now,	   although	   several	   of	   the	   trials	   should	   be	   completed,	   or	   near	  
completion,	   no	   results	   have	   been	   posted.	   A	   textual	   summary	   of	   the	   trials	   for	   digestive	  
cancers	  is	  presented	  in	  Table	  1	  (adapted	  form	  the	  Clinicaltrials.gov	  web	  site).	  
	  
Disappointingly,	   statins	   used	   as	   single	   agents	   did	   not	   demonstrate	   efficient	   cure	   of	   CRC	  
patients.	   However,	   it	   was	   observed,	   in	   a	   population	   of	   12	   000	   postmenopausal	   women	  
under	  statin	  therapy	  for	  at	  least	  3	  years,	  that	  CRC	  incidence	  was	  reduced	  by	  an	  average	  21	  
%,	  without	  specific	  effects	  according	  to	  tumor	  location,	  stage	  or	  grade	  [92].	  Statins	  reduced	  
by	  30%	  the	  incidence	  of	  metastasis	  in	  patients	  diagnosed	  with	  CRC	  [47].	  In	  addition,	  patients	  
under	   statin	   treatment	   for	   5	   years	  when	   they	  were	   diagnosed	  with	   CRC	   presented	   a	   less	  
advanced	  form	  of	  the	  disease.	  A	  clinical	  trial	  associating	  simvastatin	  and	  FOLFIRI	  suggested	  
that	   this	   drug	   combination	   could	   show	  promise	   in	  metastatic	   CRC	   [93].	   Several	   additional	  
data,	   relevant	   for	   colorectal	   cancer,	   can	   be	   found	   in	   [94].	   In	   addition,	   prostate	   cancer	  
patients	  had	  a	  reduced	  occurrence	  of	  nonorgan	  confined	  disease	  if	  taking	  statins	  at	  time	  of	  
prostatectomy,	   although	   an	   effect	   on	   cancer	   recurrence	   could	   not	   be	   demonstrated	   [29].	  
Quite	   remarkably,	  patients	  with	  advanced	   liver	  cancer	  given	  pravastatin	  showed	   increased	  
survival,	  from	  9	  to	  18	  months,	  as	  compared	  to	  placebo-­‐treated	  patients	  [95].	  In	  addition,	  as	  
amply	   supported	   by	   the	   above	   mentioned	   studies,	   combined	   treatment	   with	   statins	   and	  
anticancer	   agents	   is	   a	  much	  more	   realistic	   approach,	  which	   should	   allow	   to	   readily	   lower	  
statin	  doses,	  and	  constitutes	  the	  basis	  of	  the	  ongoing	  clinical	   trials.	   It	  seems	  reasonable	  to	  




As	  reviewed	  here,	  a	  lot	  of	  experimental	  data	  support	  the	  idea	  of	  using	  statins	  in	  cancer	  cure	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regimen.	   As	   a	   whole,	   the	   benefits	   of	   statin	   use	   are	   much	   higher	   than	   the	   deleterious	  
consequences.	   It	   is	  certainly	  a	  strong	  sign	  that	  many	  clinical	   trials	  with	  cancer	  patients	  are	  
underway	   in	   several	   countries.	   In	   this	   respect,	   it	   is	   worth	   noting	   that	   the	   Francophone	  
Federation	  of	  Digestive	  Oncology	  is	  currently	  testing	  the	  use	  of	  pravastatin	  for	  the	  treatment	  
of	  HCC	  patients	  in	  two	  separate	  trials:	  a	  phase	  III	  randomized	  trial	  in	  patients	  with	  CHILD	  A	  
(PRODIGE	   11:	   sorafenib	   vs	   sorafenib	   +	   pravastatin),	   in	   addition	   to	   the	   PRODIGE	   21	   trial	  
(Table	  1).	  No	  matter	  how	  strong	   is	   the	  experimental	  evidence	   in	   favor	  of	   statins,	  we	  need	  
these	   trials	   to	  be	   completed	   in	  order	   to	  decide	   to	   include	   statins	   as	   a	  new	  option	   for	   the	  
treatment	   of	   various	   cancers.	   Quite	   possibly,	   their	   association	   with	   bona	   fide	   anticancer	  
drugs	   or	   radiotherapy	   could	   lead	   to	   use	   statins	   in	   a	   restricted	   number	   of	   cancers,	   and	   in	  
specific	  sub-­‐populations	  of	  patients,	  taking	  individual	  metabolic	  capacities	  into	  account.	  We	  
believe	  that	  the	  recognition	  of	  statins	  as	  a	  real	  help	  in	  cancer	  treatment	  will	  be	  one	  among	  
many	  cases	  where	  already	  pathology	  targeting	  drugs	  may	  gain	  novel	  indications.	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Legends	  to	  Figures	  and	  Tables	  
Figure	   1:	   Simplified	  view	  of	   the	  cholesterol	   synthesis	  pathway,	  also	  called	   the	  mevalonate	  
pathway.	   The	   initial	   enzymes	   are	   shown	   (in	   red),	   together	   with	   the	   metabolites.	   The	  
prenylating	   metabolites	   (farnesyl	   pyrophosphate,	   FPP	   and	   geranylgeranyl	   pyrophosphate,	  
GGPP)	   and	   the	   target	   proteins	   are	   shown	   (in	   green).	   HMG-­‐CoA:	   Hydroxy	  Methyl	   Glutaryl	  
Coenzyme	  A.	  
Figure	   2:	  Main	   signal	   transduction	   cascades	   activated	   in	   response	   to	   growth	   factors.	   It	   is	  
expected	   that,	   upon	   statin	   treatment,	   Ras-­‐dependent	   pathways	   should	   be	   blunted.	   PLC:	  
Phospholipase	   C;	   PKC:	   Protein	   Kinase	   C;	   MAPK:	   Mitogen	   Activated	   Protein	   Kinase;	   MEK:	  
MAPK/Extracellular	   Regulated	   Kinase;	   Pi3K:	   Phosphatidylinositol	   Tri-­‐Phosphate	   Kinase;	  
mTOR:	  mammalian	  Target	  Of	  Rapamycin.	  
Table	  1	  :	  Ongoing	  clinical	  trials	  recorded	  at	  the	  National	  Institute	  of	  Health	  (study	  results	  are	  not	  yet	  available)	  	  
	  	   Study	  Title	   Conditions	   Intervention	   URL	  
Colorectal	  cancer	  




Care	   Drug:	  Simvastatin|Drug:	  Placebo	   http://ClinicalTrials.gov/show/NCT00994903	  
	  	  
	  
Rosuvastatin	  in	  Treating	  
Patients	  With	  Stage	  I	  or	  
Stage	  II	  Colon	  Cancer	  That	  
Was	  Removed	  By	  Surgery	  
Colorectal	  
Cancer|Precancerous	  
Condition	   Drug:	  rosuvastatin|Other:	  placebo	   http://ClinicalTrials.gov/show/NCT01011478	  
	  	  
	  
Crossover	  Evaluation	  of	  
Effect	  of	  Atorvastatin	  on	  PK	  
of	  Irinotecan	  in	  CRC	  
Patients	  Receiving	  FOLFIRI	  
Advanced	  
Adenocarcinoma	  of	  the	  




Enriched	  Inulin,	  or	  Sulindac	  
in	  Preventing	  Cancer	  in	  
Patients	  at	  Increased	  Risk	  






enriched	  inulin|Drug:	  atorvastatin	  
calcium|Drug:	  sulindac|Other:	  
placebo	   http://ClinicalTrials.gov/show/NCT00335504	  
	  	  
	  
Cetuximab	  and	  Simvastatin	  
in	  Treating	  Patients	  With	  
Advanced	  or	  Metastatic	  
Colorectal	  Cancer	   Colorectal	  Cancer	  
Biological:	  cetuximab|Drug:	  
simvastatin|Other:	  laboratory	  




Panitumumab	  in	  Treating	  
Patients	  With	  Advanced	  or	  
Metastatic	  Colorectal	  
Cancer	   Colorectal	  Cancer	  
Biological:	  panitumumab|Drug:	  
simvastatin|Other:	  laboratory	  










cetuximab/irinotecan/simvastatin	   http://ClinicalTrials.gov/show/NCT01281761	  
	  	  
	  
Trial	  of	  XELIRI/FOLFIRI	  +	  
Simvastatin	  Followed	  by	  
Simvastatin	  Maintenance	  in	  
Metastatic	  Colorectal	  
Cancer	   Colorectal	  Cancer	   Drug:	  Simvastatin	   http://ClinicalTrials.gov/show/NCT01238094	  
	  	  
	  
Phase	  II	  Study	  of	  
Simvastatin	  Plus	  Irinotecan,	  
Fluorouracil,	  and	  
Leucovorin	  (FOLFIRI)	  for	  
Metastatic	  CRC	  
Colorectal	  
Cancer|Metastasis	   Drug:	  simvastatin	   http://ClinicalTrials.gov/show/NCT00313859	  
Liver	  cancer	  
Sorafenib	  Tosylate	  With	  or	  
Without	  Pravastatin	  in	  
Treating	  Patients	  With	  Liver	  
Cancer	  and	  Cirrhosis	   Liver	  Cancer	  





assessment	   http://ClinicalTrials.gov/show/NCT01075555	  
	  	  
	  
Palliative	  Treatment	  of	  
Hepatocellular	  Carcinoma	  
in	  Patient	  With	  CHILD	  B	  




Pravastatin|Drug:	  Sorafenib	  +	  
Pravastatin|Other:	  patients	  
receiving	  best	  supportive	  care	   http://ClinicalTrials.gov/show/NCT01357486	  
	  	  
	  
Efficacy	  and	  Safety	  Study	  of	  
Sorafenib	  Plus	  Pravastatin	  
to	  Treat	  Advanced	  
Hepatocarcinoma	  
Advanced	  
Hepatocarcinoma	   Drug:	  Pravastatin	   http://ClinicalTrials.gov/show/NCT01418729	  
Gastric	  cancer	  
Trial	  of	  XP	  
(Capecitabine/CDDP)	  
Simvastatin	  in	  Advanced	  
Gastric	  Cancer	  Patients	   Gastric	  Cancer	   Drug:	  Simvastatin|Drug:	  Placebo	   http://ClinicalTrials.gov/show/NCT01099085	  
	  	  
	  
Study	  to	  Evaluate	  the	  
Efficacy	  of	  Pravastatin	  on	  




Cancer|Stomach	  Cancer	   Drug:	  Pravastatin	   http://ClinicalTrials.gov/show/NCT01038154	  
Pancreatic	  cancer	  
Trial	  of	  Simvastatin	  and	  
Gemcitabine	  in	  Pancreatic	  
Cancer	  Patients	   Pancreatic	  Cancer	  
Drug:	  
Gemcitabine+simvastatin|Drug:	  
Gemcitabine+Placebo	   http://ClinicalTrials.gov/show/NCT00944463	  
Footnote	  :	   Adapted	   from	   the	   clinicaltrials.gov	   web	   site.	   PK	  :	   pharmacokinetics	  ;	   CRC	  :	   colorectal	   cancer	  ;	   FOLFIRI	  :	  mixture	   of	   folinic	   acid,	  
fluorouracile	  and	  irinotecan	  ;	  XELIRI	  :	  mixture	  of	  capecitabine	  and	  irinotecan	  ;	  CHILD	  B	  :	  Level	  B	  of	  Child-­‐Pugh	  classification	  of	   liver	  cirrhosis	   ;	  
CDDP	  :	  cisplatin.	  


